
    
      This is a dose block-randomized, double-blind, placebo-controlled, single and multiple
      ascending dose study to assess the safety, tolerability and PK/PD profile by administering
      investigational product (IP) as a single dose (One time) or repeated doses (7 days, once a
      day) orally in a fasted state.
    
  